Gufic Biosciences — 360° view

Gufic Biosciences, a company in the Pharmaceuticals industry, reported revenue of ₹261 crore and net profit of ₹22 crore for the June 2026 quarter.

Gufic Biosciences (NSE: GUFICBIO) closed at ₹418.25 on 20 Nov 2026, up 22.1% over the past year. Its market capitalisation is ₹4,194 crore and it trades at 51.1 times earnings.

Share price
₹418.25 (20 Nov 2026)
Market cap
₹4,194 Cr (20 Nov 2026)
P/E
51.10 (20 Nov 2026)
Revenue
₹261 Cr (June 2026 quarter)
Net profit
₹22 Cr (June 2026 quarter)
ROCE
12.2% (FY26)
ROE
9.98% (FY26)
Book value
₹66.2 (FY26)
Dividend yield
0.02% (last 12 months to 20 Nov 2026)
52-week high / low
₹493.95 / ₹268.00 (20 Nov 2026)
1-year return
22.1% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: GUFICBIO

Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.